Chiltern is Designed Around You

LONDON and WILMINGTON, N.C., Nov. 3, 2014 -- With a renewed therapeutic specialization, deepened service offering and expanded geographic footprint, Chiltern launches today as a completely integrated and unified CRO with services that are "Designed Around You".

"We hear from our clients that Chiltern listens first in order to adapt to each unique relationship," said Chiltern CEO, Dr Jim Esinhart. "Our refreshed theme is a direct response, as we steadily grow to meet the needs of our customers. Chiltern's culture embraces creativity and deep engagement through the application of therapeutic expertise within a flexible global platform that is distinctly 'Designed Around You.'"

The new Chiltern provides multinational therapeutic specialization in respiratory, anti-infectives / vaccines, ophthalmology and dermatology. In addition, the Chiltern Oncology division uniquely manages all phases of clinical development in a complex, constantly evolving cancer research environment. And the Chiltern Source division provides tailored relationships for FSP, resourcing and staffing at a functional level for clinical, biometrics, medical and regulatory needs.

Chiltern will be on display at the 13th Annual Partnerships in Clinical Trials Congress, 5th-6th November in Barcelona and the 56thAnnual American Society of Hematology (ASH) Meeting and Exposition, 6th-9th December in San Francisco. Meeting requests are welcome via [email protected].

Further, Chiltern is pleased to make available its new e-book, Oncology Research Today, highlighting current developments in cancer research. This volume of five white papers can be viewed at http://oncologyresearchtoday.epubxp.com/t/150862. A limited number of hardcopies will be available by visiting Chiltern booth #541 during the ASH conference.

About Chiltern: 
Chiltern is a leading CRO that listens to client needs in order to customize solutions for the Biopharma industry. With a 32 year history, Chiltern delivers globally with therapeutic expertise in oncology, respiratory, anti-infectives / vaccines, ophthalmology and dermatology. Chiltern operates two specialty units: Chiltern Oncology is led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source is a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern's 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are "Designed Around You".

Further information is available at: http://www.chiltern.com.

For more information contact:  
Nicholas Spittal  
Sr. Director, Global Commercial Affairs  
Chiltern International Inc. 
4000 Centregreen Way, Suite 300 
Cary, NC 27513 
USA  
Tel: +1 (919) 462 8867  
Email: [email protected]

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.